TEVA
Teva Pharmaceutical Industries Limited NYSE$35.35
Mkt Cap $41.2B
52w Low $14.99
91.1% of range
52w High $37.35
50d MA $31.25
200d MA $25.88
P/E (TTM)
28.4x
EV/EBITDA
15.8x
P/B
5.1x
Debt/Equity
2.2x
ROE
19.0%
P/FCF
31.2x
RSI (14)
—
ATR (14)
—
Beta
0.76
50d MA
$31.25
200d MA
$25.88
Avg Volume
7.3M
About
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalant…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | 1M% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 29, 2026 | TNS | 0.50 | 0.53 | +6.0% | 35.38 | +1.8% | -0.9% | -1.2% | — | — | — | — | — |
| Jan 28, 2026 | TNS | 0.65 | 0.96 | +47.7% | 33.21 | +0.2% | -0.4% | +2.6% | +7.0% | +9.2% | +5.3% | +2.0% | — |
| Nov 5, 2025 | TNS | 0.68 | 0.78 | +14.7% | 24.60 | -2.2% | -0.6% | -2.6% | -1.4% | +2.2% | +5.0% | +15.7% | — |
| Jul 30, 2025 | TNS | 0.63 | 0.66 | +4.8% | 16.83 | +0.5% | -8.2% | -8.6% | -6.8% | -6.7% | -4.9% | +9.2% | — |
| May 7, 2025 | TNS | 0.47 | 0.52 | +10.6% | 17.60 | -0.5% | +2.7% | -3.8% | +2.0% | -0.7% | -4.0% | +1.0% | — |
| Jan 29, 2025 | TNS | 0.69 | 0.71 | +2.9% | 18.54 | +0.1% | -3.8% | -4.4% | -6.4% | -8.0% | -7.2% | -11.2% | — |
| Nov 6, 2024 | TNS | 0.65 | 0.69 | +6.2% | 17.43 | +1.1% | +0.4% | -1.8% | -0.3% | -1.8% | -2.8% | -0.6% | — |
| Jul 31, 2024 | TNS | 0.57 | 0.61 | +7.0% | 17.43 | -1.0% | +0.6% | -2.5% | -4.3% | -3.0% | -3.7% | +8.3% | — |
| May 8, 2024 | TNS | 0.51 | 0.48 | -5.9% | 15.74 | -0.2% | +1.7% | +3.2% | +7.2% | +8.6% | +6.6% | +6.9% | — |
| Jan 31, 2024 | TNS | 0.75 | 1.00 | +33.3% | 12.10 | +0.6% | +3.0% | +1.5% | +2.3% | +1.2% | +0.3% | +11.6% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 30 | UBS | Maintains | Buy → Buy | — | $35.38 | $36.02 | +1.8% | -0.9% | -1.2% | — | — | — |
| Apr 30 | JP Morgan | Maintains | Overweight → Overweight | — | $35.38 | $36.02 | +1.8% | -0.9% | -1.2% | — | — | — |
| Apr 30 | Piper Sandler | Maintains | Overweight → Overweight | — | $35.38 | $36.02 | +1.8% | -0.9% | -1.2% | — | — | — |
| Apr 30 | Truist | Maintains | Buy → Buy | — | $35.38 | $36.02 | +1.8% | -0.9% | -1.2% | — | — | — |
| Apr 9 | BofA Securities | Maintains | Buy → Buy | — | $30.52 | $30.45 | -0.2% | +1.4% | +1.0% | +2.1% | +4.1% | +3.6% |
| Mar 4 | Piper Sandler | Maintains | Overweight → Overweight | — | $32.28 | $33.18 | +2.8% | +2.0% | -1.6% | -3.8% | -2.4% | -2.4% |
| Feb 18 | Truist | Maintains | Buy → Buy | — | $34.41 | $34.20 | -0.6% | -0.9% | -0.2% | -0.6% | -1.5% | -1.4% |
| Feb 9 | Goldman Sachs | Maintains | Buy → Buy | — | $34.69 | $34.57 | -0.3% | -0.6% | -0.9% | -1.1% | -2.2% | -2.0% |
| Jan 30 | Barclays | Maintains | Overweight → Overweight | — | $33.07 | $32.49 | -1.8% | +3.1% | +7.4% | +9.6% | +5.7% | +5.2% |
| Jan 29 | Scotiabank | Maintains | Sector Outperform → Sector Outperform | — | $33.21 | $33.26 | +0.2% | -0.4% | +2.6% | +7.0% | +9.2% | +5.3% |
Data updated apr 27, 2026 4:30am
· Source: massive.com